🏛️ Verified NIH Record • Updated 2026-06-19
Study of BHV-1400 in IgA Nephropathy (NCT07054684)
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Biohaven Therapeutics Ltd.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Who can join: Review the eligibility criteria below.
Location: Site-001 — Farmington, Connecticut
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Site-001 — Farmington, Connecticut
- Site-003 — Miami Lakes, Florida
- Site-011 — Miami Lakes, Florida
- Site-013 — Orlando, Florida
- Site-005 — Pembroke Pines, Florida
- Site-008 — Lawrenceville, Georgia
- Site-009 — Hinsdale, Illinois
- Site-012 — Indianapolis, Indiana
- Site-015 — Shelby, Michigan
- Site-006 — Chesterfield, Missouri
- Site-002 — Dakota Dunes, South Dakota
- Site-014 — Houston, Texas
- Site-004 — Houston, Texas
- Site-016 — Salt Lake City, Utah
- Site-007 — Leicester,
📞 Contact the Study Coordinator
Phone: (203) 404-0410
Email: clinicaltrials@biohavenpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy
- A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With Proteinuric Glomerular Diseases — Glendale, California
- Atacicept in Subjects With IgA Nephropathy — Brisbane, California
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
Explore by condition: All IgA Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.